News | December 24, 2024
Syensqo and Emulseo collaborate to advance microfluidic technology in healthcare sector
Exploring new opportunities within the fast-growing market of microfluidics
Exploring new opportunities within the fast-growing market of microfluidics
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Harnessing advanced data analysis for early detection, prevention and better outcomes
Final decision from the European Commission is anticipated within the coming months
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Subscribe To Our Newsletter & Stay Updated
